| Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy P Jayaprakash, M Ai, A Liu, P Budhani, T Bartkowiak, J Sheng, C Ager, ... The Journal of clinical investigation 128 (11), 5137-5149, 2018 | 320 | 2018 |
| Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages A Obradovic, N Chowdhury, SM Haake, C Ager, V Wang, L Vlahos, ... Cell 184 (11), 2988-3005. e16, 2021 | 205 | 2021 |
| Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity CR Ager, MJ Reilley, C Nicholas, T Bartkowiak, AR Jaiswal, MA Curran Cancer immunology research 5 (8), 676-684, 2017 | 163 | 2017 |
| Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion CJ Frangieh, JC Melms, PI Thakore, KR Geiger-Schuller, P Ho, ... Nature genetics 53 (3), 332-341, 2021 | 153 | 2021 |
| Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27–Dependent Pathway T Bartkowiak, AR Jaiswal, CR Ager, R Chin, CH Chen, P Budhani, M Ai, ... Clinical Cancer Research 24 (5), 1138-1151, 2018 | 98 | 2018 |
| Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses DH Aggen, CR Ager, AZ Obradovic, N Chowdhury, A Ghasemzadeh, ... Clinical Cancer Research 27 (2), 608-621, 2021 | 90 | 2021 |
| TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma MJ Reilley, B Morrow, CR Ager, A Liu, DS Hong, MA Curran Journal for immunotherapy of cancer 7 (1), 1-9, 2019 | 72 | 2019 |
| High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege CR Ager, A Boda, K Rajapakshe, ST Lea, ME Di Francesco, ... Journal for ImmunoTherapy of Cancer 9 (8), e003246, 2021 | 46 | 2021 |
| Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype AR Jaiswal, AJ Liu, S Pudakalakatti, P Dutta, P Jayaprakash, ... Cancer Immunology Research 8 (11), 1365-1380, 2020 | 45 | 2020 |
| Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy CR Ager, H Zhang, Z Wei, P Jones, MA Curran, ME Di Francesco Bioorganic & medicinal chemistry letters 29 (20), 126640, 2019 | 35 | 2019 |
| Tumor hypoxia drives immune suppression and immunotherapy resistance M Ai, P Budhani, J Sheng, S Balasubramanyam, T Bartkowiak, ... Journal for ImmunoTherapy of Cancer 3 (2), 1-1, 2015 | 32 | 2015 |
| The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity P Ho, JC Melms, M Rogava, CJ Frangieh, J Poźniak, SB Shah, Z Walsh, ... Cancer Cell 41 (7), 1207-1221. e12, 2023 | 19 | 2023 |
| Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model CR Ager, AZ Obradovic, JM Arriaga, MG Chaimowitz, A Califano, ... Cancer Immunology Research, 2021 | 16 | 2021 |
| Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators A Obradovic, C Ager, M Turunen, T Nirschl, M Khosravi-Maharlooei, ... Cancer cell 41 (5), 933-949. e11, 2023 | 15 | 2023 |
| Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors. M Reilley, AM Tsimberidou, SA Piha-Paul, TA Yap, S Fu, A Naing, ... Journal of Clinical Oncology 37 (15_suppl), TPS2669-TPS2669, 2019 | 13 | 2019 |
| Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer JE Hawley, AZ Obradovic, MC Dallos, EA Lim, K Runcie, CR Ager, ... Cancer Cell 41 (11), 1972-1988. e5, 2023 | 7 | 2023 |
| Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial NK Altorki, ZH Walsh, JC Melms, JL Port, BE Lee, A Nasar, C Spinelli, ... Nature Communications 14 (1), 8435, 2023 | 6 | 2023 |
| The CD58: CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity P Ho, JC Melms, M Rogava, CJ Frangieh, SB Shah, Z Walsh, O Kyrysyuk, ... bioRxiv, 2022.03. 21.485049, 2022 | 6 | 2022 |
| Mechanisms underlying 4-1BB agonist antibody mediated hepatotoxicity T Bartkowiak, AR Jaiswal, M Ai, P Budhani, C Ager, MA Curran The Journal of Immunology 196 (1 Supplement), 188.5-188.5, 2016 | 4 | 2016 |
| KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response CR Ager, M Zhang, M Chaimowitz, S Bansal, S Tagore, A Obradovic, ... Journal for Immunotherapy of Cancer 11 (9), 2023 | 3 | 2023 |
